Amir Fathi MD; ASH 2025: Paradigm Study Finds Young, Fit Adults with Acute Myeloid Leukemia Do Better with Gentler Azacitidine/Venetoclax Initial Therapy

An interview with Amir Fathi MD from Massachusetts General Hospital discusses the Paradigm study presented at ASH 2025. The phase two randomized trial found that young, fit adults with acute myeloid leukemia had improved event-free survival and higher response rates with azacitidine/venetoclax initial therapy. This gentler treatment also led to fewer toxicities and better quality of life compared to standard induction chemotherapy.